The American drugmaker was one of 17 companies US President Donald Trump called on last summer to lower prices, and among the ...

Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to ...

Johnson & Johnson JNJ, through its Innovative Medicine segment, commercializes multiple blockbuster therapies spanning a wide ...

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

TrumpRx is supposed to launch in early 2026. Here's what we know about how buying medicine through the site to get discounts ...

Epithelioma Treatment Market to reach USD 13.1 billion by 2035, driven by rising skin cancer cases and growing adoption of ...

A new Reuters report, based on data from healthcare research firm 3 Axis Advisors, names Pfizer (PFE) and GSK (GSK) among the ...

We read with interest the article by Santacroce about personalised medicine in eosinophilic oesophagitis (EoE) and the ...

Phase III trial involved 594 patients across 20 countries Ceralasertib-Imfinzi combo showed no new safety concerns AstraZeneca shares fall 1% after trial results Dec 22 (Reuters) - AstraZeneca (AZN.L) ...